[Therapy of the preleukemic state: effect of androgens on refractory anemia].

Abstract

We have examined the efficacy of various drugs in 44 patients with MDS and found the different effectiveness which depends on the type of MDS. Namely, RA appears to respond to steroid hormone, androgen, and/or vitamin D3, regardless of single or combined use. In particular, it is obvious in androgen, and as our previous reports, high content of acidic ferritin in RBC with RA have changed to more basic ones by treatment with androgen. On the contrary, these drugs were not effective on RAEB, RAEB-T, and CMML. A long-term observation is needed to determine whether the prolonged or decreased occurrence of leukemia could be obtained in the effective cases with RA. Most of the cases who did not develop overt leukemia during this study died of bleeding or infections due to thrombocytopenia or leukocytopenia, thus indicating that supportive therapies are important in patients with MDS. Since it has recently been reported that recombinant G-CSF or GM-CSF is helpful to increase the number of leucocyte and to enhance their functional recovery in MDS, these factors may be powerful agents against infections when they are carefully used with regard to the activation of leukemic clones.

• Authors: K Sakurada, M Morioka, T Miyazaki
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 15 Issue 6 Pg. 1960-7 (Jun 1988) ISSN: 0385-0684 [Print] Japan
• PMID: 2838001 (Publication Type: English Abstract, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Androgens
• Cytarabine
• Cholecalciferol

Topics

• Adult
• Aged
• Androgens (therapeutic use)
• Anemia, Refractory (drug therapy)
• Anemia, Refractory, with Excess of Blasts (drug therapy)
• Blast Crisis (drug therapy)
• Cholecalciferol (therapeutic use)
• Chromosome Aberrations
• Cytarabine (therapeutic use)
• Female
• Humans
• Leukemia, Myeloid (drug therapy, pathology)
• Male
• Middle Aged
• Preleukemia (drug therapy, genetics)
• Prognosis